Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC decreased its stake in Edwards Lifesciences Co. (NYSE:EW) by 15.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 163,558 shares of the medical research company’s stock after selling 29,569 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Edwards Lifesciences were worth $12,108,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. GSA Capital Partners LLP purchased a new position in shares of Edwards Lifesciences in the third quarter worth about $481,000. Empowered Funds LLC lifted its stake in shares of Edwards Lifesciences by 10.7% in the third quarter. Empowered Funds LLC now owns 24,032 shares of the medical research company’s stock worth $1,586,000 after buying an additional 2,324 shares in the last quarter. Swiss National Bank lifted its stake in shares of Edwards Lifesciences by 0.5% in the third quarter. Swiss National Bank now owns 1,788,600 shares of the medical research company’s stock worth $118,030,000 after buying an additional 8,300 shares in the last quarter. Quest Partners LLC purchased a new position in shares of Edwards Lifesciences in the third quarter worth about $406,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in shares of Edwards Lifesciences in the third quarter worth about $7,290,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several research reports. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Piper Sandler lifted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Trading Down 0.5 %

Shares of EW stock opened at $70.31 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market capitalization of $41.33 billion, a P/E ratio of 10.09, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a 50 day moving average price of $71.61 and a 200 day moving average price of $70.35. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. The trade was a 16.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,303 shares of company stock worth $3,715,776 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.